D-0432-2023 Class II Terminated

Recalled by The Harvard Drug Group — La Vergne, TN

FDA drug recall D-0432-2023 was initiated by The Harvard Drug Group on Feb 23, 2023 and is designated Class II. Reason for recall: Packaging defect: observed packaging defect, blister packaging inadequately sealed. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 17,586 cartons.

Recall details

Product Type
Drugs
Report Date
Mar 8, 2023
Initiation Date
Feb 23, 2023
Termination Date
Apr 30, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
17,586 cartons

Product description

Carbidopa and Levodopa Tablets, USP 25 mg/100 mg, 10x10 Unit Dose carton, Rx Only, Manufactured in Czech Republic by: Teva Czech Industries, s.r.o. Opava-Komarov, Czech Republic, Manufactured for: Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, Packaged and Distributed by: Major Pharmaceuticals Indianapolis, IN 46268 USA. NDC 0904-7257-61, UPC 3 09047 25761 4

Reason for recall

Packaging defect: observed packaging defect, blister packaging inadequately sealed.

Distribution pattern

Distributed Nationwide in the USA

Code information

Lot: M04145 Exp. 01/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0432-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0432-2023. Report a data issue: hello@regdatalab.com.